{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05683678",
            "orgStudyIdInfo": {
                "id": "ALX-NF1-501"
            },
            "organization": {
                "fullName": "Alexion Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "US Selumetinib Registry",
            "officialTitle": "US Selumetinib Registry",
            "therapeuticArea": [
                "Other"
            ],
            "study": "us-selumetinib-registry"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-02-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-05",
            "studyFirstSubmitQcDate": "2023-01-05",
            "studyFirstPostDateStruct": {
                "date": "2023-01-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-08",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alexion Pharmaceuticals, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to understand treatment patterns and assess long-term effectiveness and safety outcomes associated with selumetinib treatment as well as to explore clinical and non-clinical factors affecting those outcomes in participants with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs) who were aged 2 to 18 years at the time selumetinib was started in a real-world setting.",
            "detailedDescription": "This is a US observational registry of pediatric NF1 PN participants treated with selumetinib."
        },
        "conditionsModule": {
            "conditions": [
                "Neurofibromatosis Type 1",
                "Plexiform Neurofibromas"
            ],
            "keywords": [
                "neurofibromatosis type 1",
                "plexiform neurofibromas",
                "NF1",
                "PNs"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_ONLY",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "description": "Participants who started selumetinib and discontinued selumetinib before enrollment (the \"discontinued\" cohort)."
                },
                {
                    "label": "Cohort 2",
                    "description": "Participants who started selumetinib before enrollment and are continuing to receive selumetinib at the time of enrollment (the \"continuing\" cohort)."
                },
                {
                    "label": "Cohort 3",
                    "description": "Participants who intend to initiate selumetinib within approximately 3 months after enrollment (the \"initiating\" cohort)."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Improvement in Clinically Significant Plexiform Neurofibromas (PNs) as Assessed by the Treating Physician",
                    "timeFrame": "Up to Month 60"
                },
                {
                    "measure": "Number of Participants with Improvement in Disease Status as Assessed by the Treating Physician",
                    "timeFrame": "Up to Month 60"
                },
                {
                    "measure": "Number of Participants with Improvement in Neurofibromatosis type 1 (NF1) Skeletal Manifestations",
                    "description": "Skeletal manifestations may include changes in the angle of spine curvature.",
                    "timeFrame": "Up to Month 60"
                },
                {
                    "measure": "Number of Participants with Treatment Emergent Medical Events of Interest (MEOI)",
                    "timeFrame": "Up to Month 60"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change From Baseline in the Numerical Rating Scale (NRS-11) Score at Month 60",
                    "timeFrame": "Baseline, Month 60"
                },
                {
                    "measure": "Change From Baseline in the Pain Interference Index (PII) Score at Month 60",
                    "timeFrame": "Baseline, Month 60"
                },
                {
                    "measure": "Change From Baseline in the Patient Global Impression of Change (GIC) Scale at Month 60",
                    "timeFrame": "Baseline, Month 60"
                },
                {
                    "measure": "Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) at Month 60",
                    "timeFrame": "Baseline, Month 60"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants diagnosed with NF1 and PN who were or will be aged 2 to 18 years at the time of selumetinib initiation on or after 10 April 2020 including participants who:\n* Discontinued selumetinib before enrollment; or\n* Initiated treatment before enrollment and are currently on selumetinib; or\n* Intend to initiate selumetinib within approximately 3 months after enrollment\n* Able to give written informed consent. Participant or participant's parent/legal guardian must be willing and able to give written informed consent and the participant (if minor) must be willing to give written informed assent.\n\nExclusion Criteria:\n\n* Participants currently participating in any clinical trials at time of enrollment or initiation of selumetinib.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Approximately 200 participants who meet the eligibility criteria will be enrolled from about 20 to 22 sites.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alexion Pharmaceuticals, Inc.",
                    "role": "CONTACT",
                    "phone": "1-855-752-2356",
                    "email": "clinicaltrials@alexion.com"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Albany",
                    "state": "New York",
                    "zip": "12208",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.65258,
                        "lon": -73.75623
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017253",
                    "term": "Neurofibromatoses"
                },
                {
                    "id": "D000009456",
                    "term": "Neurofibromatosis 1"
                },
                {
                    "id": "D000009455",
                    "term": "Neurofibroma"
                },
                {
                    "id": "D000018318",
                    "term": "Neurofibroma, Plexiform"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018317",
                    "term": "Nerve Sheath Neoplasms"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009386",
                    "term": "Neoplastic Syndromes, Hereditary"
                },
                {
                    "id": "D000020752",
                    "term": "Neurocutaneous Syndromes"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000010523",
                    "term": "Peripheral Nervous System Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000010524",
                    "term": "Peripheral Nervous System Neoplasms"
                },
                {
                    "id": "D000009423",
                    "term": "Nervous System Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19549",
                    "name": "Neurofibromatoses",
                    "asFound": "Neurofibromatosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12399",
                    "name": "Neurofibromatosis 1",
                    "asFound": "Neurofibromatosis Type 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12398",
                    "name": "Neurofibroma",
                    "asFound": "Neurofibromas",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20462",
                    "name": "Neurofibroma, Plexiform",
                    "asFound": "Plexiform Neurofibromas",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20461",
                    "name": "Nerve Sheath Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M12331",
                    "name": "Neoplastic Syndromes, Hereditary",
                    "relevance": "LOW"
                },
                {
                    "id": "M22509",
                    "name": "Neurocutaneous Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M13432",
                    "name": "Peripheral Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12367",
                    "name": "Nervous System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13433",
                    "name": "Peripheral Nervous System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T4096",
                    "name": "Neurofibromatosis",
                    "asFound": "Neurofibromatosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4097",
                    "name": "Neurofibromatosis Type 1",
                    "asFound": "Neurofibromatosis Type 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4095",
                    "name": "Neurofibroma",
                    "asFound": "Neurofibromas",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}